Other Information .
−Removed: Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc.
−Removed: and Silver Rock Associates, Inc., dated May 4, 2020
−Removed: Filed herewith
+Added: 10.1 †
Amendment No.
−Removed: 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc.
−Removed: and Silver Rock Associates, Inc., dated July 15, 2020
−Removed: Filed herewith
+Added: 3, dated as of October 14, 2020, to Executive
+Added: Compensation Agreement between Gerald W.
+Added: Crabtree and the Company
+Added: Incorporated by reference from the Company’s Current
+Added: Report on Form 8-K filed with the SEC on October 16, 2020.
Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
8 unchanged sentences
Filed herewith
−Removed: Interactive Data Files for the Company’s Form 10-Q for the period ended July 31, 2020
+Added: Interactive Data Files for the Company’s Form 10-Q for the period ended October 31, 2020
Submitted herewith.
+Added: Indicates a management contract or any compensatory
+Added: plan, contract or arrangement.
Pursuant to the requirements of the Securities
2 unchanged sentences
PharmaCyte Biotech, Inc.
−Removed: September 11, 2020
+Added: December 11, 2020
/s/ Kenneth L.
1 unchanged sentence
(Duly Authorized Officer and Principal Executive Officer)
−Removed: September 11, 2020
+Added: December 11, 2020
/s/ Carlos A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.